Know Rare Launches HealthStoryAI App for People Living with Rare Disease
03 déc. 2024 08h02 HE
|
Know Rare
Know Rare launches HealthStoryAI app for people living with rare disease, leveraging the latest natural language processing (NLP) technology
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
20 juin 2024 08h00 HE
|
Centogene NV
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
10 mai 2024 06h30 HE
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
01 sept. 2023 08h00 HE
|
Centogene NV
Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of...
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein
01 sept. 2023 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für seltene genetische...
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
26 avr. 2023 08h30 HE
|
Centogene NV
Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE’s FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic...
CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
12 avr. 2023 06h30 HE
|
Centogene NV
Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with...
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
17 janv. 2023 08h00 HE
|
Idera Pharmaceuticals, Inc.
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 16h05 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and...
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
17 mars 2022 06h30 HE
|
Centogene NV
In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential development of new...